Introduction
============

Urothelial cancer (UC), also called transitional cell carcinoma, accounts for more than 90% of bladder cancers, with more than 350,000 newly diagnosed cases, and causes approximately 150,000 deaths per year worldwide.[@b1-ott-9-1535] Approximately 75%--80% of cases of urothelial tumors present with non-muscle invasive disease; however, the remaining cases of advanced (muscle invasive) disease can progress to metastatic disease, and the prognosis of these patients is very poor.[@b2-ott-9-1535] Currently, platinum-based chemotherapy is the standard of care for advanced UC patients. These chemotherapy regimens include combinations such as cisplatin and gemcitabine and methotrexate, vinblastine, doxorubicin, and cisplatin.[@b3-ott-9-1535] However, platinum resistance occurs rapidly and nearly 80% of cases relapse. For these patients, there remains no consensus regarding optimal treatment. In the first and largest randomized Phase-III trial conducted by Bellmunt et al in 2009,[@b4-ott-9-1535] vinflunine chemotherapy demonstrated a 8.6% response rate with a 2.3-month survival benefit; this led to the approval of vinflunine as second-line therapy for UC by the European Medicines Agency (EMA) in 2009 but not in the USA. Recently, many cytotoxic agents,[@b5-ott-9-1535]--[@b11-ott-9-1535] as single agent or in combination, have been extensively investigated as candidate second-line chemotherapies for advanced UC. However, to our best knowledge, there are no head-to-head comparison data available for single agent versus combined chemotherapy in the treatment of previously treated patients with UC. Therefore, we performed a systematic review and meta-analysis of published data to compare treatment outcomes with single agent versus combined chemotherapy for the management of previously treated patients with UC.

Methods
=======

Study design
------------

We developed a protocol that defined inclusion criteria, search strategy, outcomes of interest, and analysis plan. The reporting of this systematic review adheres to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statements.[@b12-ott-9-1535]

Identification and selection of studies
---------------------------------------

To identify studies for inclusion in our systematic review and meta-analysis, we did a broad search of four databases, including EMBASE, MEDLINE, the Cochrane Central Register of Controlled Trials, and the Cochrane Database of Systematic Reviews, from the date of inception of every database to July 2015. The search included the following terms: "urothelial neoplasms", "urothelial carcinoma", "urothelial cancer", "chemotherapy", "previously treated", "refractory", "salvage therapy", and "clinical trials". Additional references were searched through manual searches of the reference lists and specialist journals. No language restrictions were applied.

Study populations (referred to hereafter as cohorts) with the following criteria were eligible for the study: 1) patients with UC who were refractory to previous chemotherapy; 2) patients who were under treatment with combined chemotherapy or single agent chemotherapy (patients who received molecular agent alone or chemotherapy plus molecular targeted agents were excluded for analysis in our study); 3) patients with reported outcomes of interest (ie, objective response rate \[ORR\], disease control rate \[DCR\], and 1- and 2-year overall survival \[OS\]; and 4) patients from an original study (ie, randomized controlled trial, non-randomized clinical trial, observational studies, or case series).

Data extraction
---------------

Two investigators screened the titles and abstracts of potentially relevant studies. We retrieved the full text of relevant studies for further review by the same two reviewers. A third senior investigator resolved any discrepancies between reviewers. If reviewers suspected an overlap of cohorts in a report, they contacted the corresponding author for clarification; we excluded studies with a clear overlap.

The same pair of reviewers extracted study details independently, using a standardized pilot-tested form. A third investigator reviewed all data entries. We extracted the following data: author, study design, study period, median age, interventions (chemotherapy regimens and dose), sample size, and outcomes of interest. We defined outcomes of interest as ORR, DCR, and 1- and 2-year OS. To assess quality, since we included non-comparative (uncontrolled) studies in our systematic review and meta-analysis, we used the Newcastle-Ottawa quality assessment scale.[@b13-ott-9-1535] We selected items that focused on representativeness of study patients, demonstration that the outcome of interest was not present at the start of the study, adequate assessment of outcome, sufficient length of follow-up to allow outcomes to arise, and adequacy of follow-up.

Statistical analysis
--------------------

We prespecified the analysis plan in the protocol. We analyzed all patients who started single agent or combined chemotherapy, regardless of their adherence to treatment. We calculated event rates of outcome (the proportion of patients who developed outcomes of interest) from the included cohorts for both single agent and combined chemotherapy. We pooled log-transformed event rates with DerSimonian and Laird random-effect models and assessed heterogeneity using chi-square-based *Q* statistic test.[@b14-ott-9-1535] We used the test of interaction proposed by Altman and Bland[@b15-ott-9-1535] to compare log-transformed rates of outcomes between single agent and combined chemotherapy. A statistical test with a *P*-value less than 0.05 was considered significant. To measure overall heterogeneity across the included cohorts, we calculated the *I*^2^ statistic, with *I*^2^ greater than 50% indicating high heterogeneity. We did all statistical analyses with comprehensive meta-analysis software version 2.0 (Biostat, Englewood, NJ, USA).

Results
=======

Search results
--------------

A total of 569 studies were identified from the database search, of which 70 reports were retrieved for full-text evaluation. Fifty cohorts from 49 trials met the inclusion criteria and were included in this systematic review[@b4-ott-9-1535]--[@b11-ott-9-1535],[@b16-ott-9-1535]--[@b56-ott-9-1535] ([Figure 1](#f1-ott-9-1535){ref-type="fig"}). We did not find randomized controlled trials or controlled studies that compared single agent with combined chemotherapy in previously treated patients with UC directly. [Table 1](#t1-ott-9-1535){ref-type="table"} shows the characteristics of the included studies. Overall, 1,685 patients previously treated with advanced UC were included, with a median age of 64 years for the single agent group and 65 years for the combined chemotherapy group. The median progression-free survival (PFS) and OS were higher in combined chemotherapy cohorts than single agent cohorts, while the median age did not significantly differ between groups ([Table 2](#t2-ott-9-1535){ref-type="table"}).

Methodological quality of the included studies was fair; most studies provided adequate outcome ascertainment, enrolled a representative sample of patients, and had an acceptable length of follow-up ([Figure 2](#f2-ott-9-1535){ref-type="fig"}). However, comparative evidence was at high risk of bias because we compared data across studies not within them, and selection bias was likely to be present. Assessment of publication bias was not done because data would be unreliable in view of the few studies included for each treatment group and high heterogeneity (*I*^2^\>50%) in most analyses.

Pooled incidence of primary outcomes
------------------------------------

A total of 1,556 patients were included for ORR analysis. The pooled event rate of ORR for combination chemotherapy was higher than that of single agent alone (34.5% vs 15.3%, [Table 3](#t3-ott-9-1535){ref-type="table"}). A higher incidence of DCR and 1-year OS was observed in combination chemotherapy (56.6% and 38.5%, respectively), while comparable incidence of 2-year OS was found between combination chemotherapy and single agent alone (16.1% vs 12.3%, [Table 3](#t3-ott-9-1535){ref-type="table"}).

Efficacy comparison between combination chemotherapy and single agent
---------------------------------------------------------------------

The pooled event rate of OS for combined chemotherapy was significantly higher than that for single agent chemotherapy at 1 year (relative risk \[RR\] 1.52; 95% confidence interval \[CI\]: 1.01--2.37; *P*=0.03) but not for 2-year OS (RR 1.31; 95% CI: 0.92--1.85; *P*=0.064, [Table 3](#t3-ott-9-1535){ref-type="table"}). Additionally, ORR and DCR were significantly different between combined chemotherapy and single agent (*P*\<0.001 and *P*=0.033, respectively) ([Table 3](#t3-ott-9-1535){ref-type="table"}).

Toxicity
--------

[Table 4](#t4-ott-9-1535){ref-type="table"} shows the overall occurrence of high-grade (≥ grade 3) toxic effects with single agent versus combined chemotherapy. There were significantly more toxicities of leukopenia and thrombocytopenia in the combined chemotherapy than in single agent group (*P*\<0.001 and *P*=0.024, respectively). While more incidence of fatigue was observed in single agent group when compared to combined chemotherapy (RR 0.17, 95% CI: 0.07--0.42, *P*\<0.001). Additionally, equivalent frequencies of anemia, nausea, vomiting, and diarrhea were found between single agent and combined chemotherapy ([Table 4](#t4-ott-9-1535){ref-type="table"}).

Discussion
==========

UC is the most common cancer of the urinary tract. Although platinum-based chemotherapy regimen is regarded as the gold standard for treating advanced UC patients,[@b57-ott-9-1535] there is no established treatment for these patients with progressive disease other than the first-line platinum-based chemotherapy. Due to the aggressive and rapid fatal disease course of advanced UC, the development of systematic chemotherapy using combinations of agents is rational for the salvage treatment of this disease, especially in those patients with good performance status. However, to the best of our knowledge, there is lack of head-to-head comparison data available for combination chemotherapy versus single agent alone as salvage treatment for advanced UC patients. As a result, we conducted this systematic review and meta-analysis to evaluate the efficacy of combination chemotherapy versus single agent alone as salvage treatment for advanced UC patients.

A total of 1,685 advanced UC patients from 50 cohorts are included for analysis. Based on our pooled results, we found that combined chemotherapy resulted in a statistically increased ORR, DCR, and 1-year OS but not for 2-year OS. In addition, our study indicated that combination chemotherapy was associated with more frequencies of grade 3 and 4 myelosuppression toxicities, while equivalent frequencies of anemia, nausea, vomiting, and diarrhea were found between single agent and combined chemotherapy except for fatigue. However, clinicians should be cautious when interrupting these results due to the limitation of our studies, and more evidence is still required to identify patients who will most likely benefit by the appropriate combination chemotherapy.

After we completed our study, a similar analysis of taxanes-containing combination chemotherapy versus single agent taxane in previously treated UC patients was published.[@b58-ott-9-1535] This latter study revealed that taxanes-containing chemotherapy significantly is associated with an improved OS (hazard ratio 0.60; 95% CI: 0.45--0.82; *P*\<0.001) and PFS (hazard ratio 0.61; 95% CI: 0.49--0.77; *P*\<0.001). Our study is different on several counts. First, our study included both taxanes and other chemotherapy drugs as salvage treatment for advanced UC patients, resulting in a larger sample size (1,685 versus 370 patients). Secondly, our study also assessed the ORR, DCR, and grade 3/4 toxicities with combination chemotherapy versus single agent. Importantly, despite literature review from two separate groups, using different methodology, and including some nonoverlapping trials, both studies demonstrated a significantly increased OS benefits, adding further validity to the findings.

Several limitations need to be mentioned in this analysis. First and most importantly, the application of formal meta-analytic methods to observational studies was controversial. One of the most important reasons for this is that the designs and populations of the studies were diverse and that these differences may influence the pooled estimates. However, as no head-to-head comparison data are available for combination chemotherapy versus single agent alone, a meta-analysis of observational studies is one of the few methods for assessing efficacy and toxicities.[@b59-ott-9-1535] Moreover, it represents the uncertainty surrounding the pooled estimates and is a valuable method to decide on whether more evidence is needed, which was a timely discussion topic with regard to salvage chemotherapy for advanced UC patients. Second, the study was a pooled analysis of primarily single-arm prospective studies and retrospective series, with a small number of patients included that might have overreported the benefit of preoperative treatments. The inclusion criteria also likely favor young, fit, and responder patients and a highly selected group of subjects with good prognostic indicators; all of these might cause potential selection bias. Third, we included UC patients treated with different combination or single agent chemotherapy for analysis, which would increase the clinical heterogeneity among included trials, which also made the interpretation of a meta-analysis more problematic. Additionally, we could not answer that which combination regimens would be the best choice. Finally, this meta-analysis only considered published literature, and lack of individual patient data restricted us from adjusting the treatment effect according to previous treatment and patient variables.

Conclusion
==========

Currently available clinical evidence for advanced UC patients indicates that combined chemotherapy may be a more efficient regimen for previously treated UC patients, but with more frequencies of grade 3 and 4 myelosuppression toxicities compared with single agent. However, since the overall quantity and quality of data regarding salvage chemotherapy is poor, there might be risk of bias in comparisons between observation studies. No definite conclusions were attained from the results. As a result, prospective randomized studies, definitively comparing the survival and treatment toxicity between combined chemotherapy and single agent, are strongly recommended to clearly determine the role of combined chemotherapy as salvage treatment for previously treated UC patients.
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###### 

Baseline characteristics of 50 cohort groups for meta-analysis

  Author                                   Study design   Patients, n   Chemotherapy regimen                    Median age, years   Median PFS, months   Median OS, months
  ---------------------------------------- -------------- ------------- --------------------------------------- ------------------- -------------------- -------------------
  Matsumoto et al[@b16-ott-9-1535]         R              10            GEM + Nadaplatin                        67                  8.8                  5
  Maolake et al[@b17-ott-9-1535]           R              27            Tegafur-uracil                          74                  11.9                 NR
  Naiki et al[@b18-ott-9-1535]             R              38            GEM + Doc                               66                  10.8                 4.4
  Morales-Barrera et al[@b19-ott-9-1535]   R              22            Doc                                     71                  3.12                 1.67
  Lee et al[@b20-ott-9-1535]               R              28            M-VAC                                   64                  11.4                 4.9
  Rozzi et al[@b21-ott-9-1535]             P              23            Pegylated liposomal doxorubicin         62                  6.3                  4.1
  Ko et al[@b22-ott-9-1535]                P              48            Nanoparticle albumin-bound paclitaxel   66                  10.8                 6
  Halim and Abotouk[@b23-ott-9-1535]       P              40            MTX + PTX + EPI + CBP                   62                  12.5                 12
  Bhattacharyya et al[@b24-ott-9-1535]     P              18            MFI                                     63.5                5.4                  3.4
  Tsuruta et al[@b25-ott-9-1535]           P              16            GEM + CBP + Doc                         68                  12.6                 5
  Rozzi et al[@b26-ott-9-1535]             P              35            EPI + PTX                               64                  12.6                 7.6
  Kitamura et al[@b27-ott-9-1535]          P              45            PTX + IFO + Nedaplatin                  68                  8.9                  4
  Joung et al[@b28-ott-9-1535]             R              21            PTX + DDP                               64                  9                    3
  Ikeda et al[@b29-ott-9-1535]             R              24            GEM + PTX                               64.5                12.4                 6.1
  Albers et al[@b30-ott-9-1535]            P              81            GEM + PTX short-term                    63.9                7.8                  4
  GEM + PTX long-term                      65.1           8             3.1                                                                              
  Tanji et al[@b31-ott-9-1535]             R              32            GEM + DDP                               74                  13                   5
  Suyama et al[@b32-ott-9-1535]            R              33            GEM + PTX                               66.1                11.3                 NR
  Srinivas and Harshman[@b33-ott-9-1535]   P              11            DOC + L-OHP                             65                  7                    NR
  Joly et al[@b34-ott-9-1535]              P              45            PTX                                     64                  6.9                  3.2
  Dumez et al[@b35-ott-9-1535]             P              21            Plitidepsin                             64                  2.3                  1.4
  Bellmunt et al[@b50-ott-9-1535]          P              253           Vinflunine                              NR                  6.9                  NR
  Lassiter et al[@b36-ott-9-1535]          P              23            Piritrexim                              66.2                NR                   NR
  Kanai et al[@b37-ott-9-1535]             P              20            GEM + PTX                               62.9                11.5                 NR
  Han et al[@b38-ott-9-1535]               P              30            M-VAC                                   64                  10.9                 5.3
  Uhm et al[@b39-ott-9-1535]               P              28            PTX + DDP                               61                  10.3                 6.2
  Matsumoto et al[@b40-ott-9-1535]         R              10            GEM + PTX                               66                  10.3                 4.1
  Lin et al[@b41-ott-9-1535]               P              23            GEM + IFO                               66                  4.8                  3.5
  Kouno et al[@b42-ott-9-1535]             P              35            PTX + CBP                               67                  7.9                  3.7
  Galsky et al[@b43-ott-9-1535]            P              13            Pemetrexed                              69                  NR                   NR
  Sweeney et al[@b9-ott-9-1535]            P              47            Pemetrexed                              64                  9.6                  2.9
  Fechner et al[@b44-ott-9-1535]           P              30            GEM + PTX                               66                  13                   8.5
  Culine et al[@b45-ott-9-1535]            P              51            Vinflunine                              63                  6.6                  3
  Winquist et al[@b10-ott-9-1535]          P              20            L-OHP                                   64                  7                    1.5
  Vaishampayan et al[@b46-ott-9-1535]      P              44            PTX + CBP                               64.6                6                    4
  Hoshi et al[@b47-ott-9-1535]             P              16            GEM + CBP                               68                  NR                   NR
  Vaughn et al[@b48-ott-9-1535]            P              31            PTX                                     66                  7.2                  2.2
  Pagliaro et al[@b49-ott-9-1535]          P              51            GEM + IFO                               65                  9.5                  NR
  Bellmunt et al[@b50-ott-9-1535]          P              20            MTX + PTX                               NR                  5                    3
  Albers et al[@b5-ott-9-1535]             P              30            GEM                                     NR                  8.7                  4.9
  Stenberg et al[@b51-ott-9-1535]          P              41            GEM + PTX                               NR                  14.4                 NR
  Krege et al[@b6-ott-9-1535]              P              22            DOC + IFO                               61                  NR                   NR
  De Mulder et al[@b52-ott-9-1535]         P              43            5-FU + DDP                              61                  4.9                  2.33
  Sweeney et al[@b53-ott-9-1535]           P              26            PTX + IFO                               66                  NR                   NR
  Lorusso et al[@b7-ott-9-1535]            P              31            GEM                                     64                  5                    3.8
  Witte et al[@b54-ott-9-1535]             P              56            IFO                                     NR                  NR                   NR
  Pronzato et al[@b55-ott-9-1535]          P              20            IFO                                     NR                  NR                   NR
  Papamichael et al[@b8-ott-9-1535]        P              14            PTX                                     68                  NR                   NR
  McCaffrey et al[@b11-ott-9-1535]         P              30            Doc                                     NR                  9                    NR
  Dreicer et al[@b56-ott-9-1535]           P              9             PTX                                     63                  NR                   NR

**Abbreviations:** PFS, progression-free survival; OS, overall survival; R, retrospective; P, prospective; GEM, gemcitabine; Doc, docetaxel; PTX, paclitaxel; IFO, ifosfamide; CBP, carboplatin; 5-FU, 5-fluorouracil; DDP, cisplatin; MTX, methotrexate; L-OHP, oxaliplatin; EPI, epirubicin; M-VAC, methotrexate plus vinblastine plus dororubicin plus cisplatin; MFI, methotrexate plus fluorouracil plus irinotecan; NR, not reported.

###### 

Baseline characteristics of single agent versus combined chemotherapy

  Characteristics      Single agent   Combined chemotherapy   *P*-value
  -------------------- -------------- ----------------------- -----------
  Cohorts (n)          20             30                      --
  Patients (n)         814            871                     --
  Median age (years)   64             65                      0.58
  Median PFS, m        3.0            4.25                    0.022
  Median OS, m         6.95           10.3                    0.012

**Abbreviations:** PFS, progression-free survival; OS, overall survival; m, months.

###### 

Comparison of primary outcomes for single agent versus combined chemotherapy

  Groups          Cohorts (n)   Patients (n)   Events (95% CI)     *I*^2^   Relative risk (95% CI)   *P*-value
  --------------- ------------- -------------- ------------------- -------- ------------------------ -----------
  ORR                                                                                                
   Single agent   19            709            15.3 (11.1--20.7)   55.5     1                        
   Combination    30            847            34.5 (29.7--39.6)   51.5     2.25 (1.60--3.18)        \<0.001
  DCR                                                                                                
   Single agent   13            545            50.9 (46.5--55.4)   71.8     1                        
   Combination    23            618            56.6 (52--60.1)     49.6     1.12 (1.01--1.25)        0.033
  1-year OS                                                                                          
   Single agent   8             474            25.3 (15.9--37.7)   77.2     1                        
   Combination    20            644            38.5 (34.6--42.6)   6.0      1.52 (1.01--2.37)        0.03
  2-year OS                                                                                          
   Single agent   5             379            12.3 (9.2--16.2)    23.3     1                        
   Combination    16            569            16.1 (13.1--19.6)   37.1     1.31 (0.92--1.85)        0.064

**Note:** *I*^2^≥50% suggests high heterogeneity across studies.

**Abbreviations:** ORR, objective response rate; DCR, disease control rate; OS, overall survival; CI, confidence interval.

###### 

Comparison of higher than grade 3 toxic effect event rates for single agent versus combined chemotherapy

  Toxicities                     Included study   Events   Total   Events rate (95% CI)   *I*^2^   RR (95% CI)         *P*-value
  ------------------------------ ---------------- -------- ------- ---------------------- -------- ------------------- -----------
  **Hematologic toxicity**                                                                                             
  Anemia                                                                                                               
   Single agent                  13               84       520     13.5 (9.2--19.4)       67.7     1                   
   Combination                   26               110      765     14.6 (9.9--20.9)       49.7     1.08 (0.64--1.83)   0.39
  Leukopenia                                                                                                           
   Single agent                  14               182      534     17.9 (9.2--32.1)       80.8     1                   
   Combination                   26               327      724     45.5 (35.8--55.5)      88.0     2.54 (1.31--4.93)   ,0.001
  Thrombocytopenia                                                                                                     
   Single agent                  13               37       520     9.0 (6.6--12.1)        77.7     1                   
   Combination                   26               118      724     15.9 (8.8--22.9)       40.3     1.77 (1.00--3.11)   0.024
  **Non-hematologic toxicity**                                                                                         
  Nausea                                                                                                               
   Single agent                  9                16       399     5.6 (2.3--12.8)        61.1     1                   
   Combination                   17               18       457     7.0 (4.6--10.3)        0        1.25 (0.48--3.23)   0.32
  Vomiting                                                                                                             
   Single agent                  12               24       480     6.4 (3.5--11.6)        49.1     1                   
   Combination                   16               12       419     6.0 (3.8--9.5)         0        0.93 (0.44--1.99)   0.43
  Diarrhea                                                                                                             
   Single agent                  10               10       224     7.8 (4.4--13.5)        45.7     1                   
   Combination                   12               11       327     4.9 (2.9--8.2)         0        0.63 (0.29--1.35)   0.12
  Fatigue                                                                                                              
   Single agent                  9                74       372     17.7 (9.8--29.9)       70.3     1                   
   Combination                   10               4        282     3.0 (1.5--6.1)         0        0.17 (0.07--0.42)   ,0.001

**Abbreviations:** RR, relative risk; CI, confidence interval.
